The Effect of Physiotherapy Integrated With Yoga and Mindfulness on Individuals With Fibromyalgia
PhYoMind
Physiotherapy-Integrated Yoga and Mindfulness Plus Home Exercise Versus Home Exercise Alone for Individuals With Fibromyalgia (PhYoMind): A Single-Blind, Parallel-Group, Randomized Controlled Trial
3 other identifiers
interventional
40
1 country
1
Brief Summary
The current study investigates the effect of an integrative physiotherapy and mind-body program called PhYoMind intervention on disability and symptoms in individuals with fibromyalgia (FM). Participants will be randomized to either the PhYoMind intervention, which combines specific physiotherapy techniques with yoga and mindfulness, or to a home exercise control group. The intervention lasts 8 weeks, with supervised and home sessions. The primary outcome is disability, with secondary outcomes including measures of central and autonomic nervous system function, pain perception, stress, fatigue, and sleep quality. Adverse events and adherence of the intervention will be also assessed.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Feb 2026
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 12, 2025
CompletedFirst Posted
Study publicly available on registry
August 28, 2025
CompletedStudy Start
First participant enrolled
February 10, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 30, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
May 30, 2026
May 5, 2026
August 1, 2025
4 months
August 12, 2025
April 28, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Disability, Fibromyalgia Impact Questionnaire (FIQ)
The FIQ is a valid and reliable questionnaire with a total score range of 0-100 measuring overall disease severity, pain severity, physical functioning, work difficulties, morning fatigue, depression, anxiety, and general well-being rated by individuals with fibromyalgia. Higher scores indicate a greater impact of symptoms.
At baseline (Week 0) and after 8 weeks of intervention (Week 8)
Secondary Outcomes (6)
Central Nervous System Assessment, Central Sensitization Inventory (CSI)
At baseline (Week 0) and after 8 weeks of intervention (Week 8)
Autonomic Nervous System Assessment, Heart Rate Variability (HRV)
At baseline (Week 0) and after 8 weeks of intervention (Week 8)
Pain Perception, The Visual Analog Scale (VAS)
At baseline (Week 0) and after 8 weeks of intervention (Week 8)
Fatique Assessment, The 20-item Multidimensional Fatigue Index (MFI)
At Baseline (Week 0) and after 8 weeks of intervention (Week 8)
Sleep Assessment, Pittsburgh Sleep Quality Index (PSQI)
At baseline (Week 0) and after 8 weeks of intervention (Week 8)
- +1 more secondary outcomes
Other Outcomes (3)
Demographic Data
At Baseline (Week 0)
Adverse Events
At weeks 2, 4, 6, 8
Adherence to the intervention
At weeks 2, 4, 6, 8
Study Arms (2)
PhYoMind Intervention Group
EXPERIMENTALPhysiotherapy techniques integrated with yoga and mindfulness + Home Exercise
Home Exercise Group
ACTIVE COMPARATOROnly Home Exercise (walking + strenghtening + streching)
Interventions
This integrative intervention method includes some specific physiotherapy techniques, ( e. g. self proprioceptive neuromuscular facilitation, self nerve gliding, self mobility, post isometric relaxation techniques) yoga postures, left nostril breathing, humming bee breathing and mindfulness practices. Each session will be 75 minutes and focus on different parts of the body and yoga postures will be selected according to these focused areas. For each week, a specific body area will be chosen as the focus. For example, the first week will focus on the hip area and lower extremities, the second week on the upper body and upper extremities, the third week on the core and anterior line of the body, and the fourth week on the back and posterior line of the body and this sequence will continue through the eighth week. In addition to these sessions, participants in this group will also apply home exercises (aerobic+strenghtening+streching) twice a week, 60 minutes per practice.
The control group will receive only home exercises twice a week. Big muscle groups strengthening and stretching exercises and walking planned for the patient will be given as home exercise. The walking exercise will last 30 minutes at a moderately fast pace, depending on the subject's adaptation. The strengthening exercises will last 15 minutes and will consist of 3 sets of 12 repetitions of exercises with body weight and light weights, generally targeting the back extensor muscles, core stabilization muscles, shoulder region muscles in the upper extremity and hip and knee joint muscles in the lower extremity. The stretching exercises will last 15 minutes and will include neck muscles, pectoralis major/minor, erector spina, hamstrings, quadriceps femoris muscles 1-2 times for 30 seconds each. Participants will be taught face to face with a brochure when they come for the first assessment and will be asked to do HE at home.
Eligibility Criteria
You may qualify if:
- Age ≥ 18 years
- Presence of clinically diagnosed fibromyalgia according to the American College of Rheumatology
You may not qualify if:
- Other important causes of pain other than FM
- Severe osteoarthritis that affects activities of daily living
- Severe somatic or psychiatric disorders
- Receiving another physiotherapy and/or physical exercise treatment concurrently with this study
- Practicing yoga and/or mindfulness regularly
- Not having sufficient cognitive level or not being able to participate in the sessions.
- History of acute myocardial infarction or heart failure and resulting cardiac capacity limitations.
- Uncontrolled hypertension (resting systolic/diastolic blood pressure ≥160/100 mmHg)
- Current treatment with medications known to significantly affect HRV (e.g. beta-blockers or antiarrhythmic drugs)
- Pregnancy or planned pregnancy during the study period
- Severe psychiatric disorders or insufficient cognitive abilities resulting in inability to participate in the study
- Participants must either be on a stable treatment for fibromyalgia or not receiving any treatment, with no intention to alter their treatment plan during the study period. Those who do not meet this criterion will be excluded from the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Bosch Health Campus
Stuttgart, Auerbachstraße 112, 70376, Germany
Related Publications (1)
Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Hauser W, Katz RL, Mease PJ, Russell AS, Russell IJ, Walitt B. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016 Dec;46(3):319-329. doi: 10.1016/j.semarthrit.2016.08.012. Epub 2016 Aug 30.
PMID: 27916278BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Holger Cramer, Prof. Dr.
Institute of General Practice and Interprofessional Care, University Hospital Tübingen, Tübingen, Germany
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Masking Details
- Data analysis will also be conducted blinded.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 12, 2025
First Posted
August 28, 2025
Study Start
February 10, 2026
Primary Completion (Estimated)
May 30, 2026
Study Completion (Estimated)
May 30, 2026
Last Updated
May 5, 2026
Record last verified: 2025-08
Data Sharing
- IPD Sharing
- Will not share
Due to concerns regarding participant confidentiality and data privacy, as well as compliance with ethical approval and consent agreements, individual participant data will not be shared beyond the study team.